MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Melanoma and MAPK Pathways
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

749 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
749 works in the cohort · of 4,299,418page 10 of 15

Labels cover 2 of 749 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 749 of 749 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

afffundunlabeled
Identification of RSK substrates using an analog-sensitive kinase approach
Belén Lizcano-Perret, Didier Vertommen, Gaëtan Herinckx, Viviane Calabrese, Laurent Gatto, Philippe P. Roux +1 more
2024· article· en· Journal of Biological Chemistry· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
5
citations
affunlabeled
Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in <i>BRAF</i><sup>V600</sup> mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.
Grant A. McArthur, Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Светлана Проценко +13 more
2022· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
5
citations
afffundunlabeled
JNK Gives Axons a Second Chance: Figure 1.
2006· review· en· Journal of Neuroscience· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
4
citations
fundno affunlabeled
NASH: Diagnosis and Treatment
David R. McGivern, Takahiro Masaki, Lifang Ping, Yan Yang, Paul Ingravallo, Sara E. Williford +36 more
2013· article· en· Hepatology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
4
citations
affunlabeled
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors.
J. Thaddeus Beck, Dale R. Shepard, Olivier Dumas, Rossanna C. Pezo, April A. N. Rose, Michael Ong +6 more
2024· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
3
citations
affunlabeled
307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study
Karl D. Lewis, Paolo A. Ascierto, Caroline Robert, Rodrigo Ramella Munhoz, Gabriella Liszkay, Luis De La Cruz Marino +9 more
2020· article· en· Regular and Young Investigator Award Abstracts· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
3
citations
afffundunlabeled
On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer
Fadia Boudghene-Stambouli, Mathilde Soulez, Natalia Ronkina, Anneke Dörrie, Alexey Kotlyarov, Ole Morten Seternes +2 more
2022· article· en· Cancers· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
3
citations

How this was built: Screen · Findings · About